Aptar Pharma and Dianosic Announce Exclusive Partnership to Advance the Active Resorbable Intranasal Scaffold Platform for the Treatment of Chronic Allergic Rhinitis and Chronic Rhinosinusitis ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material solutions, has again been named one of Barron’s ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies has achieved the Platinum level rating in ...
Narrow-moat Aptar’s ATR third-quarter performance continued the high note we have seen throughout 2023. We are maintaining our $132 fair value estimate following a strong quarter that reaffirmed our ...
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate The use of LuerVax® and Spray Divider™ support Aptar’s commitment to ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...
“Aptar has manufactured in Brazil for 25 years and this acquisition is expected to further reinforce our footprint in the region. It also helps position us to capitalize on Brazil’s fast-growing oral ...
Aptar Pharma and Dianosic have entered an exclusive partnership to develop an active resorbable intranasal scaffold (ARIS) platform to treat chronic allergic rhinitis (CAR) and chronic rhinosinusitis ...
CRYSTAL LAKE, Ill., January 21, 2026--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results